TBC1D22B Inhibitors
TBC1D22B inhibitors are a class of chemical compounds that specifically target and inhibit the activity of the TBC1D22B protein, which belongs to the TBC1 domain family. TBC1D22B is thought to function as a GTPase-activating protein (GAP) for Rab GTPases, which are key regulators of intracellular vesicular trafficking. Rab GTPases play a crucial role in determining the direction and specificity of vesicle transport within cells, controlling processes such as endocytosis, exocytosis, and membrane recycling. By accelerating the hydrolysis of GTP to GDP, TBC1D22B helps deactivate Rab GTPases, thereby regulating the timing and specificity of vesicle docking and fusion. Inhibiting TBC1D22B disrupts its ability to control Rab-mediated vesicle trafficking, leading to potential changes in the movement and sorting of intracellular cargo.
Studying TBC1D22B inhibitors provides researchers with critical insights into the molecular mechanisms that underlie vesicular transport and membrane dynamics. By inhibiting the function of TBC1D22B, scientists can investigate the effects of altered Rab GTPase activity and vesicular trafficking within the cell. This allows for a deeper understanding of how intracellular transport pathways are coordinated, particularly in processes that rely on the precise timing and location of vesicle fusion and cargo delivery. Furthermore, TBC1D22B inhibitors offer a unique opportunity to explore how this protein contributes to cellular organization, endosomal recycling, and the maintenance of membrane integrity. These inhibitors serve as valuable tools in research aimed at dissecting the roles of GAPs in Rab-regulated trafficking pathways, providing a more comprehensive view of the dynamic interplay between vesicles, membranes, and cytoskeletal elements essential for cellular function.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a specific inhibitor of phosphoinositide 3-kinases (PI3K). TBC1D22B has a domain that exhibits GTPase-activating activity for ADP-ribosylation factor family members, which are part of a larger group of proteins involved in vesicular trafficking pathways. PI3K signaling is crucial for many aspects of vesicular trafficking and membrane dynamics. By inhibiting PI3K, Wortmannin can disrupt membrane trafficking and fusion events, thereby functionally inhibiting the action of TBC1D22B in these processes. | ||||||
Dynamin Inhibitor I, Dynasore | 304448-55-3 | sc-202592 | 10 mg | $89.00 | 44 | |
Dynasore is a non-competitive inhibitor of dynamin, a GTPase enzyme involved in endocytic vesicle scission. TBC1D22B is implicated in vesicular trafficking and can regulate the trafficking pathways mediated by small GTPases. By inhibiting dynamin, Dynasore disrupts the endocytic pathway, a process with which TBC1D22B is associated, leading to functional inhibition of TBC1D22B's role in vesicular transport and endocytosis. | ||||||
Bafilomycin A1 | 88899-55-2 | sc-201550 sc-201550A sc-201550B sc-201550C | 100 µg 1 mg 5 mg 10 mg | $98.00 $255.00 $765.00 $1457.00 | 280 | |
Bafilomycin A1 is a specific inhibitor of the vacuolar-type H+-ATPase (V-ATPase) pump. TBC1D22B's function in vesicle formation and trafficking can be dependent on the acidification inside vesicles, which is generated by V-ATPase. By inhibiting V-ATPase, Bafilomycin A1 can disrupt the acidification, and thus the proper functioning of vesicles, which indirectly leads to the functional inhibition of TBC1D22B's role in vesicular trafficking. | ||||||
Cytochalasin D | 22144-77-0 | sc-201442 sc-201442A | 1 mg 5 mg | $165.00 $486.00 | 64 | |
Cytochalasin D is an inhibitor of actin polymerization, affecting the cytoskeleton structure. TBC1D22B is involved in vesicular trafficking processes that rely heavily on the cytoskeleton for vesicle movement and organelle positioning. By disrupting actin filaments, Cytochalasin D can impair vesicle motility and organelle distribution, indirectly inhibiting the function of TBC1D22B by hindering the transport pathways it regulates. | ||||||
ML 141 | 71203-35-5 | sc-362768 sc-362768A | 5 mg 25 mg | $137.00 $512.00 | 7 | |
ML141 is a potent and selective inhibitor of Cdc42 GTPase. TBC1D22B functions as a GTPase-activating protein (GAP) for small GTPases and may interact with Cdc42 as part of its regulatory role in vesicular trafficking. By inhibiting Cdc42, ML141 can prevent the proper functioning of this GTPase, which in turn can disrupt the pathways regulated by TBC1D22B, resulting in its functional inhibition. | ||||||
SecinH3 | 853625-60-2 | sc-203260 | 5 mg | $278.00 | 6 | |
SecinH3 is an inhibitor of cytohesins, which are guanine nucleotide exchange factors for ADP-ribosylation factors (ARFs). Since TBC1D22B is involved in regulating ARF family members, inhibition of their activation by cytohesins through SecinH3 can indirectly inhibit the functional role of TBC1D22B in vesicular trafficking by disrupting ARF-mediated processes. | ||||||
YM201636 | 371942-69-7 | sc-204193 | 5 mg | $217.00 | 6 | |
YM201636 is an inhibitor of phosphatidylinositol 4-kinase III beta (PI4KB). As TBC1D22B is implicated in vesicular trafficking, and PI4KB is essential for the phosphorylation of phosphatidylinositides, which are important for membrane trafficking, the inhibition of PI4KB by YM201636 can disrupt vesicle-mediated transport processes. This disruption can lead to functional inhibition of TBC1D22B's role in these pathways. | ||||||
hydroxychloroquine | 118-42-3 | sc-507426 | 5 g | $57.00 | 1 | |
Hydroxychloroquine is known to raise the pH in endosomes and lysosomes, which can disrupt vesicular trafficking and autophagy. TBC1D22B, through its role in vesicle formation and trafficking, relies on the acidic environment of these organelles for proper function. By increasing the pH, Hydroxychloroquine indirectly inhibits the functional role of TBC1D22B in these processes. | ||||||